EM2001F "Biosimilars in Oncology" (IM GR-012420)
To provide clinicians with both broad and oncology specific perspectives on biosimilars.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Explain the similarities and differences between biosimilars, reference biologics, and small molecule generics.
- Compare available safety and efficacy data for available biosimilars and reference biologics and the potential impact of interchangeability, extrapolation of indications, and substitution on dose/response, adverse events, and clinical outcomes.
- Summarize the key steps outlined by the FDA to demonstrate biosimilarity between a biosimilar and its reference biologic product.
Nisha Unni, M.D.
Assistant Professor, Department of Internal Medicine
Division of Hematology and Oncology
- 1.00 AMA